Buying Epclusa online from India costs only US$750 for a 12 week treatment. The process is simple, safe and affordable using Greg Jefferys Hep C Buyers Club, the world's most reliable supplier of Sofosbuvir + Velpatasvir.
Buying Epclusa online (Sofosbuvir/Velpatasvir) from India is surprisingly simple and cheap. The price of 12 weeks of Epclusa is only US$750 including shipping and insurance. The authorized generic Epclusa from India is identical to Gilead’s brand Epclusa in every way except for the color of the pill and the price.
To buy Epclusa online you simply need to provide a medical report that shows that you have Hepatitis C. On receipt of this report our doctor will write your prescription for Epclusa, this is a free service when your order Epclusa through our Hep C Buyers’ Club. Then it’s simply a matter of sending us your shipping details and payment.
Once we have these three things your Epclusa will be shipped from India within 48hours. Shipping is by express airmail and we will send you the tracking number. Delivery takes between seven and 14 days, depending on where you live.
Remember, you will be receiving the Gilead Sciences authorized version of Epclusa which is an exact replica of Epclusa except for the color of the pill and the price.
Epclusa is a medication used for the treatment of the chronic liver disease Hepatitis C and is the combination of Sofosbuvir 400 mg + Velpatasvir 100mg. The licensed version of Epclusa is chemically identical to brand-name Epclusa in its effectiveness, dosage and quality, as well as in the way it is taken. The Indian version of Epclusa has the same benefits, side effects and cure rates as brand Epclusa, in fact Epclusa made in India is identical to Epclusa made in the USA except for the name, the colour of the pill and the price.
Research shows that the combination of Sofosbuvir + Velpatasvir is the most effective pan-genotype treatment for chronic Hepatitis C if the patient has high levels of liver fibrosis or liver cirrhosis. Sofosbuvir and Velpatasvir are called Direct Acting Antivirals (DAAs) because they act directly on the Hepatitis C virus by blocking its ability to replicate. Epclusa is a pan-genotype Hep C drug, which means that it is effective against all genotypes of Hepatitis C.
Epclusa from India is made under direct license from the USA based pharmaceutical company GILEAD SCIENCES. In 2017 Gilead reached agreements with several of India’s largest pharmaceutical companies to manufacture a cheaper version of Epclusa so that people living in situations of poverty could access cheaper Hep C treatment. The version of Epclusa made in India is an exact replica of brand Epclusa and extensive independent research confirms that it has exactly the same cure rates as brand Epclusa
The price of Epclusa in the USA is around US$84,000 for a 12 week treatment. In 2016 GILEAD SCIENCES decided to license the manufacture of lower priced Epclusa in India. The reason for this was to make Epclusa affordable for people in second and third world countries. The Indian versions of Epclusa are identical to the USA version of Epclusa except in the colour of the Epclusa pill and the imprint on the pill. The price of Epclusa made in India is around 100th of the price of Epclusa in the USA. Despite the significant price difference between the USA version of Epclusa and the Indian version they both contain exactly the same ingredients of Sofosbuvir 400 mg + Velpatasvir 100mg
The cost for 12 weeks of Sofosbuvir + Velpatasvir from India will vary slightly depending on the brand simply because different brands have different pricing structures. There are no legal barriers to individuals who want to buy non-branded Epclusa for personal use to treat Hepatitis C. Importing Epclusa for personal use is completely legal in most countries.
Buying Epclusa online from India, such as VelaSof, is very easy: please email me for details. Our Hep C Buyers’ Club can organise shipment of Epclusa from India to most countries including the USA, Europe, Brazil. If you are not certain if you can import Epclusa into your country please check by using our country to country importing guide.
Greg Jefferys’ Hep C Buyers Club makes buying Epclusa online safe and simple. To buy affordable Epclusa from India you simply need to send a medical report or test result that shows that you have Hepatitis C. Our doctor inspects the medical report and uses it to write a prescription for Epclusa. Once this is done it is simply a matter of shipping and starting treatment.
If you have questions about getting Epclusa from India simply send an email to the Hep C Buyers’ Club and they will assist you with everything you need to know about buying Epclusa online. Email now by clicking here.
Epclusa became available globally in 2016, however, the price of over US$84,000 per treatment made it too expensive for most people. Then Gilead licensed the manufacture of Epclusa in India and it became available in May 2017.
Gilead’s agreement with licensed Indian manufacturers of Epclusa required that GILEAD handed over all the manufacturing technology for Epclusa so that the Indian version of Epclusa would be chemically identical to the Epclusa available in the USA or Europe. In return, as well as a royalty from all sales, GILEAD required that the quality and ingredients of the Indian Epclusa be EXACTLY the same as brand Epclusa.
Licensed manufacturers of Epclusa pay GILEAD a royalty for all Epclusa sold in India and other countries.
The Indian version of Epclusa gives exactly the same cure rates as the brand Epclusa. Numerous independent trials have been conducted comparing Epclusa from the USA with Epclusa made in India and all of these trials came up with the same results. Indian versions of Epclusa have exactly the same cure rates as the brand Epclusa. Click this link to see results of independent studies of Epclusa cure rates
Epclusa is effective against all genotypes of Hepatitis C and is particularly useful for patients infected with Hepatitis C genotype 3 and also for patients who have liver cirrhosis.
Epclusa is much more effective than Mavyret if a patient has liver cirrhosis or high liver fibrosis levels.
If you have Hep C genotype 1 there is no real advantage in using Epclusa over Harvoni as both give the same cure rates.
If you have G2 than Sofosbuvir + Daclatasvir will be slightly more effective than Epclusa ( Sofosbuvir +Velpatasvir). The graph below compares Epclusa with Sofosbuvir + Daclatasvir for the treatment of Hep C genotype 3 and Hep C genotype 2. This study was of 5,400 patients from the Department of Veterans Affairs.
For the treatment of Genotype 3, Epclusa (Sofosbuvir + Velpatasvir) is equal to, or superior to, all other Hepatitis C treatments, particularly if a patient has liver cirrhosis.
If you do not know what genotype of Hepatitis C you have then Epclusa is a very good idea.
Another good reason for using Epclusa is that about 10% of people with Hepatitis C are infected with more than one genotype. By using Epclusa all genotypes will be treated.
Epclusa offers a number of advantages to people with Hep C. Firstly, Epclusa treats all genotypes of Hep C. This means that if you do not know which genotype of Hep C you have then using Epclusa will save you the cost of getting a genotype test. Epclusa is also generally considered to be the most effective treatment for Hep C Genotype 3
Epclusa is made by GILEAD, the same company that manufactures Sovaldi (Sofosbuvir 400 mg) and Harvoni (Sofosbuvir 400 mg + Ledipasvir 90 mg).
Whilst Harvoni was, and still is, the optimum treatment for Hep C genotype 1 it is not the best treatment for all other genotypes of Hepatitis C, which, up until the release of Epclusa, were best treated by the combination of Sofosbuvir 400 mg + Daclatasvir 60 mg.
So GILEAD put in a lot of work to find a drug combination based around Sofosbuvir that would work against all genotypes of Hep C.
That mission was completed with the arrival of Epclusa which is made of Sofosbuvir 400 mg + Velpatasvir 100 mg.
Whilst Epclusa is not any better for treating G1 than Harvoni it is equal to, or a little better than, Sofosbuvir + Daclatasvir for treating all other genotypes of Hep C.
However, the big advantage of Epclusa is that a person does not need to know their genotype of Hep C to begin treating the virus because Epclusa will treat all genotypes of Hepatitis C thus removing the need to take the Hep C genotype test.
For a lot of people, this is a big saving in money terms because the test for genotype generally costs over US$200.
Of course like all GILEAD products, with a price tag of around US$84,000 for 12 week’s treatment Epclusa, is very expensive and out of the reach of most people who need treatment for chronic Hepatitis C. This means that Epclusa is only affordable to people with top-level health insurance or living in wealthy countries that can afford to include it in their National Health Services.
For the other 100 million+ people with Hep C using Epclusa from India is a good treatment option.
If you are thinking about buying Epclusa online from India its interesting to know a little more about the history of Epclusa; for example “Why is Epclusa so expensive in the USA and so cheap in India?”.
When Epclusa was released in the USA and Europe the price for a 12-week treatment was US$84,000. However, the Indian patent office had not recognised Gilead’s patent of Sofosbuvir (Epclusa’s key component) so Indian pharmaceutical companies were ready to manufacture Epclusa without any consultation with GILEAD. So that it would no miss out on potential income from sales in places like Asia and Africa Gilead entered into negotiations with Indian pharmaceutical companies to produce a licensed local version of Epclusa. Because part of the license agreement is that the Indian manufacturers will have access to all of GILEAD’s intellectual property, including the technology for improving absorption of Velpatasvir, this means that the Indian Epclusa is identical to the GILEAD branded Epclusa.
As with Harvoni two Indian pharmaceutical companies are making Epclusa, these are Natco and Hetero Pharmaceuticals.
Both of these companies finalised licensing agreements with GILEAD to manufacture Epclusa late in 2016 and this became available for sale from India was May 2017.